Annovis BioAdvance News Portfolio News

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

By WebmasterDecember 14, 2021November 1st, 2024No Comments

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases

Previous PostRelmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
Next PostImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers